MelaFind Device Approved to Detect Melanoma

A deadly form of skin cancer

WEDNESDAY, Nov. 2 (HealthDay News) -- MelaFind -- a device that creates digital images of suspicious skin growths and compares them to a database of thousands of scans to analyze for signs of melanoma skin cancer -- has been approved by the U.S. Food and Drug Administration.

The non-invasive diagnostic can help doctors decide whether to biopsy skin growths in their early stages, when skin cancer is nearly 100 percent curable, device maker Mela Sciences said in a news release.

Melanoma, if not caught in its earliest stages, is the deadliest form of skin cancer. It accounts for about 75 percent of skin cancer deaths, the company said.

While the new technology can recommend to doctors whether to perform a biopsy, it is not intended to confirm a clinical diagnosis of melanoma, Mela said.

The company is based in Irvington, N.Y.

More information

The U.S. National Cancer Institute has more about melanoma.

Scott Roberts

Related Articles

Learn More About Sharp
Sharp HealthCare is San Diego's health care leader with seven hospitals, two medical groups and a health plan. Learn more about our San Diego hospitals, choose a Sharp-affiliated San Diego doctor or browse our comprehensive medical services.

Health News is provided as a service to Sharp Web site users by HealthDay. Sharp HealthCare nor its employees, agents, or contractors, review, control, or take responsibility for the content of these articles. Please read the Terms of Use for more information.